Minoxidil in the treatment of androgenetic alopecia.
Study Design
- Тип исследования
- Review
- Вмешательство
- Minoxidil in the treatment of androgenetic alopecia. Up to 5% concentration (OTC approved in US)
- Препарат сравнения
- Placebo
- Направление эффекта
- Positive
- Риск систематической ошибки
- Unclear
Abstract
The National Institutes of Health (US NIH, 2018) estimates that in the US approximately 50 million men and 30 million women suffer from AGA (also known as pattern hair loss). Minoxidil is the only topical drug for the treatment of both female and male pattern hair loss. In the US, minoxidil is approved over-the-counter (OTC) at a maximum concentration of 5%. In this review, we summarize the findings of the pivotal studies used in support of the drug's approval as well as recent discoveries and novel developments in the use of minoxidil for the treatment of AGA.
Used In Evidence Reviews
Similar Papers
Annual review of nutrition · 2004
Secular trends in dietary intake in the United States.
Journal of the American Academy of Dermatology · 2002
A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
Journal of the American Academy of Dermatology · 2017
The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.
Current problems in dermatology · 2015
Alopecia areata.
Drug design, development and therapy · 2019
Minoxidil and its use in hair disorders: a review.
Journal of cosmetic dermatology · 2021